ÂÜÀòÂÒÂ×

Michael Gallo is a Senior Scientist at Obsidian Therapeutics, with a career spanning over two decades in molecular biology and biopharmaceutical research. Previously held positions include Research Scientist at Obsidian Therapeutics, Research Scientist at Pfizer, where responsibilities included leading antibody engineering initiatives, and various roles at Epic Therapeutics/Baxter Healthcare, U.S. Genomics Inc., Ontogeny/Curis, and Genetics Institute/Wyeth, focusing on assay development, gene expression, and nucleic acid delivery systems. Michael Gallo holds a B.S. in Microbiology from the University of Massachusetts Amherst.